Cellectar Biosciences Inc...

NASDAQ: CLRB · Real-Time Price · USD
4.37
-0.05 (-1.13%)
At close: Aug 15, 2025, 3:59 PM
4.41
0.92%
After-hours: Aug 15, 2025, 07:05 PM EDT

Cellectar Biosciences Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Cash & Equivalents
11.04M 13.91M 23.29M 34.26M 25.87M 40.03M 9.56M 18.99M 5.15M 12.68M 19.87M 17.79M 24.81M 30.63M 35.7M 40.34M 46.78M 53.63M
Short-Term Investments
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Long-Term Investments
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Long-Term Assets
29.78K 29.78K 29.78K 29.78K 29.78K 29.78K 29.78K 29.78K 29.78K 69.43K 81.21K 81.21K 81.21K 81.21K 81.21K 81.21K 81.21K 81.21K
Receivables
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Inventory
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Current Assets
1.58M 987.5K 961.66K 1.64M 2.04M 1.34M 888.23K 1.12M 456.68K 1.16M 663.24K 975.94K 479.67K 760.42K 867.49K 1.05M 347.03K 774.89K
Total Current Assets
12.62M 14.89M 24.25M 35.9M 27.91M 41.37M 10.45M 20.11M 5.61M 13.85M 20.53M 18.76M 25.29M 31.39M 36.57M 41.39M 47.12M 54.4M
Property-Plant & Equipment
1.05M 1.12M 1.19M 1.36M 1.45M 1.51M 1.59M 1.41M 869.73K 922.59K 978.98K 477.04K 525.95K 514.43K 549.13K 479.25K 531.76K 581.96K
Goodwill & Intangibles
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Total Long-Term Assets
1.08M 1.15M 1.22M 1.39M 1.48M 1.54M 1.62M 1.44M 899.51K 992.02K 1.06M 558.25K 607.16K 595.64K 630.35K 560.46K 612.98K 663.17K
Total Assets
13.7M 16.04M 25.47M 37.29M 29.38M 42.91M 12.08M 21.55M 6.51M 14.84M 21.59M 19.32M 25.89M 31.99M 37.2M 41.95M 47.74M 55.06M
Account Payables
n/a 3.87M 611K 8.3M 6.46M 7.39M 5.62M 7.81M 6.39M 6.9M 2.56M 6.37M 5.46M 4.51M 1.42M 3.03M 3.39M 4.9M
Deferred Revenue
n/a n/a n/a n/a n/a n/a n/a -7.81M -6.39M -6.9M n/a -6.37M -5.46M -4.51M 2.44M -3.03M -3.39M -4.9M
Short-Term Debt
92.02K n/a 84.42K 80.82K 77.35K 73.99K 58.98K 56.26K 53.64K 51.11K 50.85K 148.2K 143.84K 139.59K 135.45K 131.41K 127.48K 123.64K
Other Current Liabilities
5.77M 2.06M 5.74M 11.85M 8.55M 8.73M 7.2M 16.36M -53.64K -51.11K 865.6K -148.2K -143.84K -139.59K 368.46K -131.41K -127.48K -123.64K
Total Current Liabilities
5.87M 6.02M 9.39M 20.31M 15.17M 16.27M 12.94M 16.47M 6.45M 6.96M 5.53M 6.52M 5.61M 4.65M 3.99M 3.17M 3.52M 5.02M
Long-Term Debt
361.49K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Long-Term Liabilities
n/a 1.38M 1.38M 1.38M n/a n/a n/a 17.92M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Total Long-Term Liabilities
361.49K 1.77M 1.79M 1.81M 453.51K 474.35K 494K 18.43M 530.86K 548.34K 552.98K 53.77K 92.21K 129.71K 166.29K 201.97K 236.06K 269.31K
Total Liabilities
6.23M 7.79M 11.18M 22.13M 15.62M 16.74M 13.43M 34.9M 6.98M 7.5M 6.08M 6.57M 5.7M 4.78M 4.16M 3.37M 3.75M 5.29M
Total Debt
453.51K 474.35K 494K 512.75K 530.86K 548.34K 552.98K 569.01K 584.5K 599.45K 603.83K 201.97K 236.06K 269.31K 301.74K 333.38K 363.53K 392.95K
Common Stock
18.00 461.00 461.00 406.00 358.00 332.00 207.00 99.00 97.00 97.00 94.00 61.00 61.00 611.00 611.00 611.00 553.00 527.00
Retained Earnings
-259.39M -253.95M -247.34M -244.99M -230.32M -239.06M -217.48M -210.03M -196.3M -188.08M -179.5M -172.28M -164.47M -157.04M -150.9M -144.98M -139.16M -133.13M
Comprehensive Income
n/a n/a n/a n/a n/a -331 -207 n/a -1.38M n/a n/a n/a 0.00 n/a n/a n/a n/a n/a
Shareholders Equity
6.09M 8.25M 14.29M 15.16M 12.38M 26.17M -1.36M 4.57M -467K 7.33M 15.51M 12.75M 20.19M 27.21M 33.05M 38.59M 43.98M 49.78M
Total Investments
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a